NES
ALXN

New England Securities’s Alexion Pharmaceuticals ALXN Stock Holding History

New England Securities’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$17K Sell
92
-125
-58% -$23.2K 0.01% 942
2014
Q3 		$36K Hold
217
– – 0.01% 720
2014
Q2 		$34K Sell
217
-1
-0.5% -$158 0.01% 733
2014
Q1 		$33K Buy
218
+51
+31% +$8.11K 0.01% 678
2013
Q4 		$22K Sell
167
-27
-14% -$3.24K 0.01% 806
2013
Q3 		$23K Buy
194
+13
+7% +$1.43K 0.01% 732
2013
Q2 		$17K Buy
+181
New +$17.4K 0.01% 732

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

New England Securities's ALXN Position: Q4 2014 in Review

New England Securities reduced its Alexion Pharmaceuticals (ALXN) stake by 58% in Q4 2014, selling an estimated $23.2K and leaving 92 shares worth $17K. The position accounts for 0.01% of the portfolio, ranked #942.

New England Securities first reported a position in ALXN in Q2 2013 and has held it in 7 quarters since. The position peaked at $36K in Q3 2014. 579 funds tracked by Wall St. Rank hold ALXN as of Q4 2014.

  • New England Securities held 92 shares of Alexion Pharmaceuticals worth $17K as of Q4 2014.
  • New England Securities sold 125 Alexion Pharmaceuticals shares in Q4 2014, an estimated $23.2K.
  • Alexion Pharmaceuticals made up 0.01% of New England Securities's portfolio in Q4 2014, its #942 holding.
  • New England Securities first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 7 quarters since.
  • New England Securities's Alexion Pharmaceuticals position peaked at $36K in Q3 2014.
  • 579 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2014.

Based on New England Securities's 13F filing for Q4 2014, filed 26 Jan 2015.